BriaPro subsidiary reports $317K net loss, $1 cash, going concern doubt

BriaCell Therapeutics Corp.

Net loss of $316,517 for nine months ended April 30, 2024; zero revenue.
Cash and equivalents of $1; current liabilities $356,734; shareholders' deficit $301,924.
Going concern warning: dependent on future financing, significant doubt.
Intangible assets (patents) of $203,614 from August 2023 spin-out from BriaCell.
Operating loss of $366,960 for the nine-month period, R&D expense $227,249.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.